Slide 1: Uscom (UCM) – Global Medical Devices and Revenue Growth
October 2015 New York For personal use only Uscom (UCM) – Global Medical Devices and Revenue Growth Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO The Measure of Life
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: Disclaimer
For personal use only 3 Disclaimer
Slide 4: Uscom
Uscom For personal use only “A rapidly growing Australian medical device company with world leading products and a strategic global vision…” 4
Slide 5: Uscom: Products generate profit
Uscom For personal use only “Products generate profit” Outstanding science Experienced and sector leading people High growth (+50% pa), innovative medical device company Key cardiovascular pulmonary markets with multiple products De-risked technology Strategic growth from recent acquisitions Valuabl
Slide 6: For personal use only
For personal use only 6
Slide 7: Uscom vision
Uscom vision For personal use only Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards “A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy” 7
Slide 8: Current Business
Current Business For personal use only Premium noninvasive cardiovascular and pulmonary monitoring devices Addressing the growing threat of superbugs, heart failure, hypertension and asthma Validated, clinically accepted, cost and life saving devices with critical applications IP protected w
Slide 9: Strategic growth
Strategic growth For personal use only Complementary products and technology Fluid, Sepsis Hypertension & COPD & Heart Failure Vascular Health & Asthma US 1.3bn market * US 1.7bn market * US 400m market * CAGR of 7.6% * CAGR of 11.5% * CAGR of 6.5% * CE, FDA, TGA, CFDA CE, FDA, TGA
Slide 10: USCOM 1A
USCOM 1A For personal use only Non invasive, accurate, compact technology platform solution Heart failure, hypertension, sepsis Accurate cardiac output Works with all other hospital equipment Cardiac stroke volume Intuitive touch screen Systemic vascular Real time data resistance Platform technology
Slide 11: Uscom BP+
Uscom BP+ For personal use only Central BP - New Wave Supra-systolic Oscillometry Central Blood Pressure and Pulse Pressure Wave Analysis The new standard for hypertension • FDA, CE Mark, TGA approvals • Home or clinic • Supra-systolic • PPW Analysis Central BP+ • Results in • Reliable and 30 second
Slide 12: Uscom Thor Spirometry
Uscom Thor Spirometry For personal use only Thor (Uscom) – High fidelity digital Ultrasonic spirometry For asthma, COPD, and drug compliance monitoring • Digital ultrasonic spirometry • Dual path ultrasonic sensing • FDA, CE, and TGA approvals • Reliable and accurate • Auto calibration • Research, h
Slide 13: De-Risked technology
De-Risked technology For personal use only Featured in 400+ peer reviewed publications and presentations Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsi
Slide 14: Global People
Global People For personal use only Nick Schicht Steve Haken Andrew Kenig Denise Pater Tina Wu Rik Denicke Rob Phillips Global Euro Aus Global Global USA Global Bev Jacobson Richard Scott George Tang Lindy Belleza George Ferenczi Hagay Gilad Steve Wilson Global Global Aus Aus Global Aus USA 14
Slide 15: Results - Growth
Results - Growth For personal use only Revenue and Income Distribution Agreements $2,500,000 40 38 $2,039,426 $2,000,000 35 30 27 $1,500,000 $1,377,716 25 $1,010,942 20 $1,000,000 15 12 10 $500,000 5 $0 0 2013 2014 2015 2013 2014 2015 Current revenue only from USCOM 1A BP+ and Thor revenue in 2016 1
Slide 16: New Acquisition
New Acquisition For personal use only Uscom has acquired 100% of Thor Laboratories - Asthma * Company Overview Uscom benefits High fidelity digital Doppler spirometers Cash flow positive, revenue of $500k Established manufacturing - 15 years Accredited international manufacturing Global re
Slide 17: New Products – Asthma & COPDs
New Products – Asthma & COPDs For personal use only Products in Market New Products Digital Doppler Spirometer New - SpiroSpacer Home use Drug delivery measure Telemetry to iPhone app Smart spacer Patient interactive With Diagnostics and WIFI Digital wifi spirometer New - SpiroNet Digital wifi spiro
Slide 18: Thor Manufacturing
Thor Manufacturing For personal use only Global approvals Manufacturing and R&D Experienced engineers Established reputation USCOM and BP+ reserve University Budapest links Internationally ISO accredited medical device manufacturing 15
Slide 19: People and Manufacturing
People and Manufacturing For personal use only Post acquisition headcount Total Headcount Combined Headcount 40 7 35 34 6 Manufacturing and engineering 30 5 25 Headcount 20 +183% 4 3 15 Thor 12 2 Uscom 10 7 5 1 0 0 Uscom 2011 Uscom 2015 Uscom 2016 More people and More Manufacturing = More Revenue 19
Slide 20: Revenue Targets
Revenue Targets For personal use only Thor Total Revenue 20,000,000 18,000,000 16,000,000 BP+ 14,000,000 12,000,000 Thor $ 10,000,000 BP+ USCOM 8,000,000 USCOM 6,000,000 4,000,000 2,000,000 0 2015 2016* 2017* 2018* 2019* 2020* 20 $20m revenue by 2020 - 5 year CAGR of 58%
Slide 21: Operations growth
Operations growth 1. Uscom Aus Maintaining growth 2. 3. Uscom UK Uscom Budapest For personal use only 4. Uscom USA • • •• 2 • •• • •• 3 • • • •• • •• • 4 • • •• •• • • • • • • • • Key Markets •• 1. AsiaPAC – 65% • • • 1 2/3. Europe – 27% 4. Nth America – 8% US Focus 2016 Stephen Wilson – Former VP C
Slide 22: US Marketing
For personal use only 22 US Marketing
Slide 23: The Future: Value Cascade
The Future For personal use only Value Cascade Products Sales Operations Opportunities USCOM 1A New appointments Global operations Share price growth Uscom BP+ Current distribution Increased products Dividend Spirotube Thor distribution Increased scale Transaction Otthon of Completion New distributi
Slide 24: Multiple Products
Multiple Products For personal use only Three product ranges entering profit phase Global Profit Concept Product Pilot Validation Regulatory Revenue Distribution 2016 USCOM ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓ Uscom BP+ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ±✓ Thor ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Investment to Profit 26 IP shifting to profit
Slide 25: Industry comparators
Industry comparators For personal use only Reported and Predicted EBITDA Capitalilsed Value 2 100 1.5 92 1.5 FY 15 90 1 0.8 FY16* 80 0.5 FY 17* 70 0 61 0 60 x6 AUD (m) UCM ACG ADH AUD (m) -0.5 50 -1 40 -1.5 -1.1 -1.2 30 x4 -2 -1.6 20 15 -2.5 -2.3 10 -3 -2.6 0 -3 UCM ACG ADH -3.5 UCM -Ben Kakoschke –
Slide 26: Disconnect between performance and price!
ASX:UCM For personal use only Disconnect between performance and price! UCM share price Revenue and Income $4,000,000 $3,500,000 $3,500,000 $3,000,000 $2,500,000 $2,039,426 $2,000,000 $1,500,000 $1,377,716 $1,010,942 $1,000,000 $500,000 $0 2013 2014 2015 2016* 9 Tightly held, few traders, difficult
Slide 27: New Research
New Research For personal use only 5th Oct 2015 5th Oct 2016 12mth Change 0.14c (14m) 0.42c (42m) +200% 12 month Projections and price and cap value targets 9 Ben Kakoschke – 5th October, 2015
Slide 28: Uscom
Uscom For personal use only Value investment ✓ Experienced management ✓ Strong underlying business ✓ Strong growth phase ✓ Invested in future growth ✓ Premium global markets ✓ Diversified and lifesaving technologies✓ Aggressive global growth strategy ✓ Two new product ranges for market in the next 1
Slide 29: Thanks
October 2015 New York For personal use only Uscom (UCM) – Global Medical Devices and Revenue Growth Thanks Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO
Slide 30: USCOM 1A Competitive Advantage
USCOM 1A Competitive Advantage For personal use only Non- SV beat Method Manufacturer Technology Rel+Rep invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Samsung BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ Deltex D
Slide 31: Testimonials
Testimonials For personal use only “This machine is saving lives, there are no two ways about it.” Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia “USCOM has changed the way I look at the cardiovascular status of my patients. It’s part of t
Slide 32: BP+ Competitive Advantage
BP+ Competitive Advantage For personal use only Uscom BP+ TensioMed BPLab IEM Centron AtCor Australia Hungary Russia Germany UK Australia USD 3,500 USD 6,000 USD 7,000 USD 7,000 USD 6,300 USD 20,000 1 min 2 min 2 min 2 min 1 min 1 min Stand-alone ABP, needs computer ABP, needs computer ABP, needs co
Slide 33: Why?
Why ? For personal use only Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars BP+ is on the international space station 36 McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current e
Slide 34: Thor Competitive Advantage
Thor Competitive Advantage For personal use only Uscom Thor Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD Australia USA Switzerland Spain USA Italy USA Switzerland SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus USD 1,890 USD 2,100 USD 1